Download PDF
Handchir Mikrochir Plast Chir 2008; 40(4): 230-238
DOI: 10.1055/s-2008-1038926
Übersichtsarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Mammakarzinom im lokalisierten Stadium – Strategien für die systemisch-adjuvante Therapie

Early-Stage Breast Cancer – Strategies for Adjuvant Systemic TherapyM. Görner1 , M. Just2 , S. Gerull1
  • 1Hämatologie und Onkologie, Städtische Kliniken Bielefeld Mitte
  • 2Tagesklinik, Onkologische Schwerpunktpraxis, Bielefeld
Further Information

Publication History

eingereicht 27.4.2008

akzeptiert 29.7.2008

Publication Date:
20 August 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die systemische adjuvante Therapie ist ein integraler Bestandteil der Therapie von Frauen mit Mammakarzinomen in lokalisierten Stadien und trägt wesentlich zur Reduktion der Brustkrebsmortalität bei. Entscheidungen hinsichtlich der Therapieauswahl in der adjuvanten Therapie sind sehr komplex geworden und bedürfen einer individualisierten Risikobeurteilung, die nicht nur klinisch-pathologische Kriterien wie Tumorgröße und Lymphknotenstatus berücksichtigt, sondern auch molekulare Prädiktoren des biologischen Verhaltens des Tumors mit einbezieht. Durch die Entwicklung von zielgerichteten Therapien gegen HER-2 und durch die Verfügbarkeit von Aromatase-Inhibitoren der dritten Generation, sind neue Therapieoptionen verfügbar, die in Therapiealgorithmen integriert werden müssen. In dieser Übersichtsarbeit diskutieren wir die Leitlinien und Empfehlungen zur systemischen adjuvanten Therapie bei Mammakarzinomen in lokalisierten Stadien auf der Basis der gegenwärtigen Risikoklassifikation.

Abstract

Systemic adjuvant treatment is an integral component in the treatment of women with early-stage breast cancer and contributes significantly to the reduction of breast cancer-specific mortality. Decisions regarding adjuvant treatment modalities are becoming increasingly complex and demand individualised risk assessments based not only on clinicopathological criteria such as tumour size and axillary lymph node status but also on molecular predictors of the biological behaviour of the cancer. In addition, with the development of targeted therapies targeting HER-2 and with the availability of third generation aromatase inhibitors, new therapeutic options are available and need to be integrated into the treatment algorithms. In this review, we discuss the guidelines and recommendations concerning adjuvant systemic treatment of early-stage breast cancer based on current risk classifications.

Schlüsselwörter

Brustkrebs im lokalisierten Stadium - zielgerichtete Therapie - adjuvante systemische Therapie

Key words

early‐stage breast cancer - targeted therapy - adjuvant systemic treatment

Literatur

  • 1 Albanell J, Bellmunt J, Molina R, Garcia M, Caragol I, Bermejo B. et al . Node-negative breast cancers with p 53(−)/HER2-neu(−) status may identify women with very good prognosis.  Anticancer Res. 1996;  16 1027-1032
    PubMedGoogle Scholar
  • 2 Bardou V J, Arpino G, Elledge R M, Osborne C K, Clark G M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.  J Clin Oncol. 2003;  21 1973-1979
    CrossrefPubMedGoogle Scholar
  • 3 Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C C, Dantis L. et al . Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.  J Clin Oncol. 1996;  14 737-744
    CrossrefPubMedGoogle Scholar
  • 4 Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A. et al . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.  Cancer. 2003;  98 1802-1810
    CrossrefPubMedGoogle Scholar
  • 5 Berry D A, Cirrincione C, Henderson I C, Citron M L, Budman D R, Goldstein L J. et al . Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.  Jama. 2006;  295 1658-1667
    CrossrefPubMedGoogle Scholar
  • 6 Carlson R W, Brown E, Burstein H J, Gradishar W J, Hudis C A, Loprinzi C. et al . NCCN Task Force Report: Adjuvant therapy for breast cancer.  J Natl Compr Canc Netw. 2006;  4 (Suppl 1) S1-S26
    CrossrefPubMedGoogle Scholar
  • 7 Chia S, Bryce C, Gelmon K. The 2000 EBCTCG overview: a widening gap.  Lancet. 2005;  365 1665-1666
    CrossrefPubMedGoogle Scholar
  • 8 Coates A S, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes J F. et al . Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.  J Clin Oncol. 2007;  25 486-492
    CrossrefPubMedGoogle Scholar
  • 9 Ellis M J, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F. et al . Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB‐1- and/or ErbB‐2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.  J Clin Oncol. 2001;  19 3808-3816
    CrossrefPubMedGoogle Scholar
  • 10 Ellis M J, Ma C. Letrozol in the neoadjuvant setting: the P024 trial.  Breast Cancer Res Treat. 2007;  105 33-43
    CrossrefPubMedGoogle Scholar
  • 11 Fisher B, Bauer M, Wickerham D L, Redmond C K, Fisher E R, Cruz A B. et al . Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update.  Cancer. 1983;  52 1551-1557
    Google Scholar
  • 12 Fisher B, Slack N H. Number of lymph nodes examined and the prognosis of breast carcinoma.  Surg Gynecol Obstet. 1970;  131 79-88
    PubMedGoogle Scholar
  • 13 Goldhirsch A, Glick J H, Gelber R D, Coates A S, Thurlimann B, Senn H J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.  Ann Oncol. 2005;  16 1569-1583
    CrossrefPubMedGoogle Scholar
  • 14 Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thurlimann B, Senn H J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.  Ann Oncol. 2007;  18 1133-1144
    CrossrefPubMedGoogle Scholar
  • 15 Goss P E, Ingle J N, Martino S, Robert N J, Muss H B, Piccart M J. et al . A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.  N Engl J Med. 2003;  349 1793-1802
    CrossrefPubMedGoogle Scholar
  • 16 Henderson I C, Berry D A, Demetri G D, Cirrincione C T, Goldstein L J, Martino S. et al . Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.  J Clin Oncol. 2003;  21 976-983
    CrossrefPubMedGoogle Scholar
  • 17 Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes J F. et al . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.  Lancet. 2005;  365 60-62
    CrossrefPubMedGoogle Scholar
  • 18 Hudis C A. Trastuzumab–mechanism of action and use in clinical practice.  N Engl J Med. 2007;  357 39-51
    CrossrefPubMedGoogle Scholar
  • 19 Kaufmann M, von Minckwitz G, Bear H D, Buzdar A, McGale P, Bonnefoi H. et al . Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.  Ann Oncol. 2007;  18 1927-1934
    CrossrefPubMedGoogle Scholar
  • 20 Lohmann C, Gibney E, Cotsonis G, Lawson D, Cohen C. Progesterone receptor immunohistochemical quantitation compared with cytosolic assay: correlation with prognosis in breast cancer.  Appl Immunohistochem Mol Morphol. 2001;  9 49-53
    CrossrefPubMedGoogle Scholar
  • 21 Li X, Lewis M T. Chemotherapy increases chemo-resistant cell population with stem cell properties in breast cancer patients. San Antonio Breast Cancer Symposium 2006. 
    Google Scholar
  • 22 Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J P, Weaver C. et al . Adjuvant docetaxel for node-positive breast cancer.  N Engl J Med. 2005;  352 2302-2313
    CrossrefPubMedGoogle Scholar
  • 23 Mauri D, Pavlidis N, Ioannidis J P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.  J Natl Cancer Inst. 2005;  97 188-194
    CrossrefPubMedGoogle Scholar
  • 24 Modlich O, Prisack H B, Bojar H. Breast cancer expression profiling: the impact of microarray testing on clinical decision making.  Expert Opin Pharmacother. 2006;  7 2069-2078
    CrossrefPubMedGoogle Scholar
  • 25 Olivotto I A, Bajdik C D, Ravdin P M, Speers C H, Coldman A J, Norris B D. et al . Population-based validation of the prognostic model ADJUVANT! for early breast cancer.  J Clin Oncol. 2005;  23 2716-2725
    CrossrefPubMedGoogle Scholar
  • 26 Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M. et al . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.  N Engl J Med. 2004;  351 2817-2826
    CrossrefPubMedGoogle Scholar
  • 27 Piccart-Gebhart M J, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I. et al . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.  N Engl J Med. 2005;  353 1659-1672
    CrossrefPubMedGoogle Scholar
  • 28 Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer.  Oncology. 2001;  61 (Suppl 2) 73-82
    CrossrefPubMedGoogle Scholar
  • 29 Rastogi P, Anderson S J, Bear H D, Geyer C E, Kahlenberg M S, Robidoux A. et al . Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B‐18 and B‐27.  J Clin Oncol. 2008;  26 778-785
    CrossrefPubMedGoogle Scholar
  • 30 Roche H, Fumoleau P, Spielmann M, Canon J L, Delozier T, Serin D. et al . Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.  J Clin Oncol. 2006;  24 5664-5671
    CrossrefPubMedGoogle Scholar
  • 31 Romond E H, Perez E A, Bryant J, Suman V J, Geyer Jr C E, Davidson N E. et al . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.  N Engl J Med. 2005;  353 1673-1684
    CrossrefPubMedGoogle Scholar
  • 32 Saphner T, Tormey D C, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy.  J Clin Oncol. 1996;  14 2738-2746
    PubMedGoogle Scholar
  • 33 Schiff R, Massarweh S, Shou J, Osborne C K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.  Clin Cancer Res. 2003;  9 447S-454S
    PubMedGoogle Scholar
  • 34 Slamon D, Eiermann W, Robert N. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her-2neu positive early breast cancer patients. San Antonio, TX: Proceedings of the 29th Annual San Antonio Breast Cancer Symposium, Dec. 14 – 17, 2006. 
    Google Scholar
  • 35 Smith I, Procter M, Gelber R D, Guillaume S, Feyereislova A, Dowsett M. et al . 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.  Lancet. 2007;  369 29-36
    CrossrefPubMedGoogle Scholar
  • 36 Thomssen C, Janicke F, Harbeck N. Clinical relevance of prognostic factors in axillary node-negative breast cancer.  Onkologie. 2003;  26 438-444
    CrossrefPubMedGoogle Scholar
  • 37 Tormey D C, Gray R, Falkson H C. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.  J Natl Cancer Inst. 1996;  88 1828-1833
    CrossrefPubMedGoogle Scholar

Dr. med. MD, MBA Martin Görner

Hämatologie und Onkologie
Städtische Kliniken Bielefeld Mitte

Teutoburger Straße 50

33604 Bielefeld

Email: martin.goerner@sk-bielefeld.de

      >